103.35
前日終値:
$106.52
開ける:
$106.57
24時間の取引高:
1.71M
Relative Volume:
2.04
時価総額:
$6.07B
収益:
$551.35M
当期純損益:
$-189.33M
株価収益率:
-31.40
EPS:
-3.2916
ネットキャッシュフロー:
$-35.09M
1週間 パフォーマンス:
-14.04%
1か月 パフォーマンス:
-11.64%
6か月 パフォーマンス:
-2.77%
1年 パフォーマンス:
+8.94%
Glaukos Corp Stock (GKOS) Company Profile
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
GKOS
Glaukos Corp
|
103.35 | 6.26B | 551.35M | -189.33M | -35.09M | -3.2916 |
|
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-27 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | 開始されました | Goldman | Buy |
| 2025-05-01 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-12-11 | アップグレード | Citigroup | Neutral → Buy |
| 2024-12-06 | 開始されました | UBS | Buy |
| 2024-12-02 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-05-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-12-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-04 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-11-28 | 開始されました | Truist | Buy |
| 2023-11-08 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | 開始されました | Mizuho | Neutral |
| 2022-12-19 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-12-12 | アップグレード | Citigroup | Neutral → Buy |
| 2022-10-14 | 再開されました | Stephens | Overweight |
| 2022-10-04 | 開始されました | Needham | Buy |
| 2022-07-12 | アップグレード | Stifel | Hold → Buy |
| 2022-02-03 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | アップグレード | BTIG Research | Neutral → Buy |
| 2021-11-03 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-07-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-01-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | アップグレード | Citigroup | Sell → Neutral |
| 2020-12-09 | 開始されました | Oppenheimer | Perform |
| 2020-11-17 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-06-15 | 開始されました | Jefferies | Hold |
| 2020-03-05 | 開始されました | Citigroup | Sell |
| 2020-02-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-01-06 | アップグレード | Berenberg | Hold → Buy |
| 2019-12-12 | ダウングレード | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | 開始されました | BTIG Research | Neutral |
| 2018-08-30 | 開始されました | Berenberg | Hold |
| 2018-08-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-08-03 | 繰り返されました | Stifel | Hold |
| 2018-06-21 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-04-13 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-01 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2017-03-02 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-01-06 | アップグレード | Stifel | Hold → Buy |
| 2016-10-27 | 開始されました | Wells Fargo | Outperform |
すべてを表示
Glaukos Corp (GKOS) 最新ニュース
Glaukos (GKOS) director exercises 15,000 options at $24.69 - Stock Titan
Goldman Sachs Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $153 - Moomoo
Midday Stock Roundup: TTM Drops on Investor Day - Orange County Business Journal
Glaukos Corp. Stock Hits Day Low of $118.64 Amid Price Pressure - Markets Mojo
Glaukos (GKOS) Faces Selling Pressure Amid iDose Procedure Conce - GuruFocus
Glaukos slides 8% as investors appear to take profits after a strong run, with recent insider-sale filings adding pressure - Quiver Quantitative
Nvidia To Rally More Than 123%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
GKOS Maintained by BTIG -- Price Target Raised to $162 - GuruFocus
Glaukos wins permanent J-code for Epioxa keratoconus therapy - MSN
BTIG raises Glaukos stock price target to $162 on product pipeline - Investing.com
Glaukos director Kliman sells $703,800 in stock By Investing.com - Investing.com Nigeria
Glaukos Corp stock (US3773221029): 52-week high and fresh insider sale stir investor interest - AD HOC NEWS
Glaukos director Kliman sells $703,800 in stock - Investing.com
Director at Glaukos (NYSE: GKOS) exercises options and sells 5,000 shares - Stock Titan
Glaukos stock hits 52-week high at $146.90 By Investing.com - Investing.com Nigeria
Glaukos stock hits 52-week high at $146.90 - Investing.com UK
DNB Asset Management AS Grows Stock Position in Glaukos Corporation $GKOS - MarketBeat
Glaukos Corp stock (US3773221029): eye-care specialist gains attention after FDA approval and strong - AD HOC NEWS
Glaukos (GKOS) price target increased by 12.59% to 154.96 - MSN
Janus Henderson Group (GKOS) discloses 5.35M shares, 9.2% holding - Stock Titan
Glaukos (GKOS) Stock Price, News & Analysis - MarketBeat
Gilbert H. Kliman (GKOS) files Form 144 to sell 5,000 shares - Stock Titan
Glaukos stock (US3773221029): Director sale signals confidence near 52-week highs - AD HOC NEWS
Glaukos director Gilbert H Kliman sells $675,000 of company stock - Investing.com UK
Glaukos director Gilbert H Kliman sells $675,000 of company stock By Investing.com - Investing.com South Africa
TradingKey - TradingKey
Glaukos Corp stock (US3773221029): Insider files Form 144 for 5,000-share sale - AD HOC NEWS
Glaukos Announces Participation in Upcoming Investor Conferences - PharmiWeb.com
How to watch Glaukos at four upcoming investor conferences - Stock Titan
[144] GLAUKOS Corp SEC Filing - Stock Titan
Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Number of shareholders of Glaukos Corp – LS:A14VCK - TradingView
Glaukos Corp stock (US3773221029): Raised 2026 sales guidance lifts medtech profile - AD HOC NEWS
Glaukos Corp. Hits New 52-Week High at $145.50, Reflecting Strong Growth - Markets Mojo
Glaukos SVP & CFO Alex Thurman sells $1.4m in shares - Investing.com Australia
Glaukos SVP & CFO Alex Thurman sells $1.4m in shares By Investing.com - Investing.com South Africa
Glaukos president & COO Gilliam sells $2.8m in company stock - Investing.com Australia
Glaukos president & COO Gilliam sells $2.8m in company stock By Investing.com - Investing.com South Africa
Glaukos (GKOS) CFO exercises options and sells 10,000 shares under plan - Stock Titan
Glaukos Corp (GKOS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):